📇 Rhumatologue · CAEN CEDEX 9 · (14) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
20 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
150.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
15
15 articles ont été cités au moins 15fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 261
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
120
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
22
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre hospitalier universitaire d'Orléans
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial
2026ArticleJCO precision oncology
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
2025ArticleNature Communications
Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
2025ArticleClinical Cancer Research
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
2025ArticleAnnals of Oncology
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer
2024ArticleOncologist
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
2022ArticleGynecologic Oncology
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
2022ArticleGynecologic Oncology
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
2020ArticleGynecologic Oncology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHU CAEN
AV COTE DE NACRE, 14033 CAEN CEDEX 9
CH - SAINT-LO
715 R DUNANT CS 65509, 50009 ST LO CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
BMC public health · 2013
AbstractBackgroundIncidence of acute rheumatic fever (ARF) and prevalence of rheumatic heart disease (RHD) in the Pacific region, including New Caledonia, are amongst the highest in the world. The main priority of long-term management of ARF or RHD is to ensure secondary prophylaxis is adhered to. The objectives of this study were to evaluate rates of adherence in people receiving antibiotic prophylaxis by intramuscular injections of penicillin in Lifou and to determine the factors associated with a poor adherence in this population.MethodsWe conducted a retrospective cohort study and we included 70 patients receiving injections of antibiotic prophylaxis to prevent ARF recurrence on the island of Lifou. Patients were classified as “good-adherent” when the rate of adherence was ≥80% of the expected injections and as “poor-adherent” when it was <80%. Statistical analysis to identify factors associated with adherence was performed using a multivariate logistic regression model.ResultsOur study showed that 46% of patients from Lifou receiving antibiotic prophylaxis for ARF or RHD had a rate of adherence <80% and were therefore at high risk of recurrence of ARF. Three independent factors were protective against poor adherence: a household with more than five people (odds ratio, 0.25; 95% confidence interval [CI], 0.08 to 0.75), a previous medical history of symptomatic ARF (odds ratio, 0.20; 95% CI, 0.04 to 0.98) and an adequate healthcare coverage (odds ratio, 0.21; 95% CI 0.06 to 0.72).ConclusionsTo improve adherence to secondary prophylaxis in Lifou, we therefore propose the following recommendations arising from the results of this study: i) identifying patients receiving antibiotic prophylaxis without medical history of ARF to strengthen their therapeutic education and ii) improving the medical coverage in patients with ARF or RHD. We also recommend that the nurse designated for the ARF prevention program in Lifou coordinate an active recall system based on an updated local register. But the key point to improve adherence among Melanesian patients is probably to give appropriate information regarding the disease and the treatment, taking into account the Melanesian perceptions of the disease.
Aging · 2015
Gynecologic oncology · 2023
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
JCO precision oncology · 2026 · Journal Article
Blanc-Durand F, You B, Adnani Y, De Rauglaudre G, et al.
Nature communications · 2025 · Journal Article
Joly F, Leary A, Ray-Coquard I, Asselain B, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2025 · Journal Article
Collet L, Ardin M, Venet D, Berthet J, et al.
Gynecologic oncology · 2023 · Randomized Controlled Trial
Ferron G, De Rauglaudre G, Becourt S, Delanoy N, et al.
Gynecologic oncology · 2022 · Clinical Trial, Phase II
Joly F, Fabbro M, Berton D, Lequesne J, et al.
Gynecologic oncology · 2022 · Clinical Trial, Phase II
Trédan O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al.
European journal of nuclear medicine and molecular imaging · 2021 · Journal Article
Aide N, Fauchille P, Coquan E, Ferron G, et al.
Breast (Edinburgh, Scotland) · 2020 · Clinical Trial, Phase II
Hardy-Bessard AC, Brocard F, Clatot F, Lortholary A, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013 · Clinical Trial, Phase II
Weber B, Largillier R, Ray-Coquard I, Yazbek G, et al.
NPJ genomic medicine · 2026 · Journal Article
Blanc-Durand F, Yaniz Galende E, Ferron G, Kaminsky MC, et al.
Oxford medical case reports · 2024 · Case Reports
Adjadé G, Haag K, Meunier J, El Fadli M, et al.
Gynecologic oncology · 2020 · Clinical Trial, Phase II
Robelin P, Tod M, Colomban O, Lachuer J, et al.
Aging · 2015 · Journal Article
Falandry C, Horard B, Bruyas A, Legouffe E, et al.
BMC public health · 2013 · Journal Article
Gasse B, Baroux N, Rouchon B, Meunier JM, et al.
Oncotarget · 2016 · Journal Article
Cox DG, Curtit E, Romieu G, Fumoleau P, et al.
Aging · 2015 · Journal Article
Falandry C, Horard B, Bruyas A, Legouffe E, et al.
Breast (Edinburgh, Scotland) · 2020 · Clinical Trial, Phase II
Hardy-Bessard AC, Brocard F, Clatot F, Lortholary A, et al.
Health and quality of life outcomes · 2020 · Journal Article
Pompilus F, Ciesluk A, Strzok S, Ciaravino V, et al.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Abstract Background Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combi
Additional file 1: of Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Table S1. List of 94 variants associated with risk, involved in the 94-SNP risk score (identification and characteristics of variants). (XLS 41 kb)
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Abstract Background Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combi
Additional file 1: of Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Table S1. List of 94 variants associated with risk, involved in the 94-SNP risk score (identification and characteristics of variants). (XLS 41 kb)
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Neural regeneration research · 2020 · Journal Article
Wong So J, Largeau B, Beau-Salinas F, Ehrmann S, et al.
Breast cancer research : BCR · 2017 · Journal Article
Curtit E, Pivot X, Henriques J, Paget-Bailly S, et al.
NPJ breast cancer · 2017 · Journal Article
Pivot X, Romieu G, Fumoleau P, Rios M, et al.
Occupational medicine (Oxford, England) · 2016 · Journal Article
Meunier J, Fautrel B, Roquelaure Y, Claudepierre P